Health Canada Approves Sandoz's Generic Semaglutide, a Third Ozempic Competitor

Health Canada has approved Sandoz Canada's semaglutide injection, a generic version of Novo Nordisk's Ozempic, making it the third semaglutide generic authorized in Canada after Dr. Reddy's Laboratories and Apotex. Sandoz announced the approval on September 18, 2026. The new product is approved only for the once-weekly treatment of type 2 diabetes in adults, to improve glycemic control in combination with diet and exercise -- it is not approved for weight management, unlike some other semaglutide products on the Canadian market. The approval is most relevant to community pharmacies dispensing GLP-1 therapy, though Sandoz has not yet set a launch date.

Michel Robidoux, President and General Manager of Sandoz Canada, said the company aims "to reduce barriers to access, both financially and in terms of supply." Sandoz's product is approved in two pen formats matching Ozempic's own SKUs: one delivering 0.25 mg or 0.5 mg doses (from a 2 mg pen, 1.34 mg/mL) and one delivering a 1 mg dose (from a 4 mg pen), both as once-weekly subcutaneous injections. Sandoz says it is "taking the necessary steps to prepare for future commercialization" but has not given a specific timeline for when the product will reach pharmacy shelves.

The timing is notable: this approval arrives while Canada's two existing semaglutide generics are both in officially declared shortages. Dr. Reddy's Semaglutide Injection has been an actual shortage since July 2026 due to a manufacturing disruption, and Apotex's Apo-Semaglutide Injection was newly declared an actual shortage on September 15, citing demand overflow from Dr. Reddy's ongoing disruption and inventory now on weekly allocation. A third approved generic could eventually ease that squeeze, but approval is not the same as availability -- Sandoz's own language points to a commercialization process still getting underway, not an imminent launch.

Practice guidance for pharmacists

• Do not tell patients or prescribers that a Sandoz generic is available yet -- this is a regulatory approval, not a launch; check with your wholesaler before making it part of any supply conversation.
• Remember Sandoz's semaglutide is approved for type 2 diabetes only, not weight management, when it does reach the market -- confirm the indication on the prescription matches the approved use before dispensing.
• Continue treating Dr. Reddy's and Apotex's products as actively short with no published end date; a third manufacturer's approval does not change current stock realities.
• Watch for Sandoz's own launch announcement and Health Canada Notice of Compliance listing before updating your ordering systems or patient-facing materials.
• Keep patients who ask about "a new generic Ozempic" informed that it has been approved but is not yet available, so expectations match the actual timeline rather than the approval headline.

Sandoz says more than 12 million semaglutide injection pens are used in Canada annually, underscoring the scale of demand a third generic manufacturer could eventually help meet. For now, pharmacists have no new product to dispense, and the practical supply picture for patients seeking a lower-cost semaglutide option remains unchanged.